Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID‐19 Pandemic
暂无分享,去创建一个
J. Blay | R. Maki | E. de Álava | M. Eriksson | A. Gronchi | J. Martín-Broto | S. Stacchiotti | C. Valverde | Shreyaskumar R Patel | F. Gouin | B. Kasper | D. Donati | E. Palmerini | M. Sunyach | C. A. D. de Mello | D. Moura | N. Hindi | M. Chacón | J. Martínez-Tláhuel | H. Martínez-Said | S. Aguiar | F. C. Muñoz-Casares | F. Waisberg | M. L. G. Silva | E. Ortiz-Cruz | Ronald Badilla-González | V. Castro-Oliden | R. Correa-Generoso | Martín Falla-Jimenez | Gisela German | Juan Haro-Varas | Natalia Jiménez-Brenes | Paula Martínez-Delgado | Jose Manuel Morales-Pérez | S. Nakagawa | M. Chacon
[1] A. Dingemans,et al. Impact of the COVID-19 pandemic on cancer treatment: the patients’ perspective , 2020, European Journal of Cancer.
[2] D. Kerr,et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study , 2020, The Lancet.
[3] J. Blay,et al. Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] I. J. Douglas,et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. , 2020, medRxiv.
[5] I. Nagtegaal,et al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands , 2020, The Lancet Oncology.
[6] H. Kourie,et al. Cancer patients and research during COVID-19 pandemic: A systematic review of current evidence , 2020, Critical Reviews in Oncology/Hematology.
[7] S. Fröhling,et al. Caring for patients with cancer in the COVID-19 era , 2020, Nature Medicine.
[8] G. Curigliano,et al. A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID‐19) Pandemic: An International Collaborative Group , 2020, The oncologist.
[9] T. Burki. Cancer guidelines during the COVID-19 pandemic , 2020, The Lancet Oncology.
[10] C. Booth,et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic , 2020, Nature Reviews Clinical Oncology.
[11] G. Putoto,et al. COVID-19 in Italy: momentous decisions and many uncertainties , 2020, The Lancet Global Health.
[12] Yong-tang Zheng,et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients , 2020, Cellular & Molecular Immunology.
[13] P. Mehta,et al. COVID-19: consider cytokine storm syndromes and immunosuppression , 2020, The Lancet.
[14] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[15] Y. Hu,et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.
[16] M. Heinrich,et al. INVICTUS: A phase III, interventional, double-blind, placebo-controlled study to assess the safety and efficacy of ripretinib as ≥ 4th-line therapy in patients with advanced gastrointestinal stromal tumors (GIST) who have received treatment with prior anticancer therapies (NCT03353753) , 2019, Annals of Oncology.
[17] K. S. Hall,et al. Results of the first interim assessment of rEECur, an international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma. , 2019, Journal of Clinical Oncology.
[18] J. Martín-Broto,et al. Relevance of Reference Centers in Sarcoma Care and Quality Item Evaluation: Results from the Prospective Registry of the Spanish Group for Research in Sarcoma (GEIS). , 2018, The oncologist.
[19] J. Blay,et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. , 2019, The Lancet. Oncology.
[20] S. Sleijfer,et al. Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018 .
[21] S. Sleijfer,et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] S. Sleijfer,et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[23] S. Sleijfer,et al. Corrections to "Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up". , 2018 .
[24] M. Stevens,et al. Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): a multicentre, open-label, randomised controlled, phase 3 trial. , 2018, The Lancet. Oncology.
[25] S. Sleijfer,et al. Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first‐line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer‐Soft Tissue and Bone Sarcoma Group (EORTC‐STBSG) , 2018, International journal of cancer.
[26] J Bogaerts,et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] J. Mora,et al. GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS) , 2017, British Journal of Cancer.
[28] H. Hoekstra,et al. Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers , 2017, Annals of Surgical Oncology.
[29] J. Blay,et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. , 2017, The Lancet. Oncology.
[30] K. S. Hall,et al. Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort , 2017, Acta oncologica.
[31] Robin L. Jones,et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Steven J Durning,et al. Is There a Consensus on Consensus Methodology? Descriptions and Recommendations for Future Consensus Research , 2016, Academic medicine : journal of the Association of American Medical Colleges.
[33] J. Blay,et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial , 2016, The Lancet.
[34] M. Piccart,et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[35] N. Araki,et al. Trabectedin monotherapy after standard chemotherapy versus best supportive care in patients with advanced, translocation-related sarcoma: a randomised, open-label, phase 2 study. , 2015, The Lancet. Oncology.
[36] P. Casali,et al. Sorafenib and everolimus combination in non-resectable high-grade osteosarcoma progressing after standard treatment: a non-randomized phase II clinical trial from the Italian Sarcoma Group. Abstract , 2022 .
[37] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[38] P. Dileo,et al. What is the role of routine follow-up for localised limb soft tissue sarcomas? A retrospective analysis of 174 patients , 2014, British Journal of Cancer.
[39] Deepak Mittal,et al. New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.
[40] B. Feldman,et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. , 2014, Journal of clinical epidemiology.
[41] B. Bui,et al. Adherence to consensus-based diagnosis and treatment guidelines in adult soft-tissue sarcoma patients: a French prospective population-based study. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[42] P. Rutkowski,et al. What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib? , 2013, Medical Oncology.
[43] J. Blay,et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.
[44] W. Tap,et al. Long‐term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high‐grade, operable osteosarcoma , 2012, Cancer.
[45] J. Blay,et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). , 2012, The oncologist.
[46] M. Stevens,et al. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[47] David Goldstein,et al. Complete Longitudinal Analyses of the Randomized, Placebo-Controlled, Phase III Trial of Sunitinib in Patients with Gastrointestinal Stromal Tumor following Imatinib Failure , 2012, Clinical Cancer Research.
[48] J. Blay,et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial , 2012, The Lancet.
[49] Aki Vehtari,et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. , 2012, JAMA.
[50] J. Maurel,et al. Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] A. Ferrari,et al. Prolonged 14‐day continuous infusion of high‐dose ifosfamide with an external portable pump: Feasibility and efficacy in refractory pediatric sarcoma , 2010, Pediatric blood & cancer.
[52] K. Sepkowitz,et al. Nosocomial infections in patients with cancer. , 2009, The Lancet. Oncology.
[53] Paul A Meyers,et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] P. Thall,et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[55] P. Thall,et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] Xin Huang,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[57] N. Jaffe,et al. High‐dose ifosfamide in relapsed pediatric osteosarcoma: Therapeutic effects and renal toxicity , 2005, Pediatric blood & cancer.
[58] I. Ray-Coquard,et al. Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[59] S. Donaldson,et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. , 2003, The New England journal of medicine.
[60] Sigrid Stroobants,et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study , 2001, The Lancet.
[61] M Bonetti,et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] A. Rydholm,et al. Monitoring referral and treatment in soft tissue sarcoma: Study based on 1,851 patients from the Scandinavian Sarcoma Group Register , 2001, Acta orthopaedica Scandinavica.
[63] R. Souhami,et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma , 1999 .
[64] M. van Glabbeke,et al. A phase II study of cisplatin, ifosfamide and doxorubicin in operable primary, axial skeletal and metastatic osteosarcoma. European Osteosarcoma Intergroup (EOI). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[65] A. Antón,et al. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS) , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.
[66] H. Avet-Loiseau,et al. Ifosfamide and etoposide in childhood osteosarcoma. A phase II study of the French Society of Paediatric Oncology. , 1997, European journal of cancer.
[67] A. Giuliano,et al. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] E. Mindell,et al. cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma. , 1978, Cancer treatment reports.
[69] R. Benjamin,et al. Adriamycin: a new effective agent in the therapy of disseminated sarcomas. , 1975, Medical and pediatric oncology.